Expert Review of Clinical Pharmacology (ERCP)

Expert Review of Clinical Pharmacology [ISSN 1751-2433]; [e-ISSN 1751-2441] is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles and original papers on all aspects of clinical safety, tolerability, efficacy and therapeutic applications. The journal also covers toxicity issues, adverse reactions, pharmacoeconomics, and societal issues. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore, the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery. Please note that the journal does not publish preclinical or Phase I-II studies, unless there is a clear indication for translational medicine. Each article is structured to incorporate the author's own expert opinion on the impact of the topic on research and clinical practice and the scope for future development. Expert Review of Clinical Pharmacology aims to address the needs of clinical and pharmaceutical researchers, drug development specialists, physicians, and other specialists and players who are actively meeting such challenges in modern biomedical practice. The Editors welcome novel research in the following key areas: ADME studies and PK/PD modelling Novel clinical trial design and conduct Toxicity and carcinogenesis Adverse effects/reactions, drug–drug and drug–disease interactions Pharmacogenetics, genomics and the incorporation of new biomarkers in drug development and clinical practice Pharmacoepidemiology, risk management and pharmacovigilance Pharmacotherapy in specific groups of people, such as children, women, the immunocompromised, and different ethnicities Impact on quality of life and pharmacoeconomic issues Regulation of drug development and marketing Epidemiology and biostatistics

Expert Review of Clinical Pharmacology (ERCP) is :-

• International, Peer-Reviewed, Open Access, Refereed, clinical safety, tolerability, efficacy, safety and toxicity testing, Toxicity and carcinogenesis, Novel clinical trial design and conduct, ADME studies, PK/PD modelling , Online or Print , Bi-Monthly Journal

• UGC Approved, ISSN Approved: P-ISSN P-ISSN: 1751-2433, E-ISSN: 1751-2441, Established: 2008, Impact Factor: 3.6
• Provides Crossref DOI

• Not indexed in Scopus, WoS, DOAJ, PubMed, UGC CARE